BioStock: Evaxion brings in Per Norlén as CEO

With the recently initiated phase IIb trial in melanoma, Evaxion Biotech has entered a new, advanced clinical development phase with its portfolio of AI-driven immunotherapies. The company is ready to build a solid commercial profile and pursue strong partnerships to bring its products to market to help millions of cancer patients worldwide. A significant step in that direction was appointing industry veteran Per Norlén to the CEO position. BioStock reached out to the new CEO and Evaxion’s Chair of the Board, Marianne Soegaard, to learn more about this important transition for the company.

Read the interview with Marianne Soegaard and Per Norlén at biostock.se:

Evaxion brings in Per Norlén as CEO - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/